CN112924694A - Discrimination-free protein thermal stability analysis method - Google Patents
Discrimination-free protein thermal stability analysis method Download PDFInfo
- Publication number
- CN112924694A CN112924694A CN201911240786.3A CN201911240786A CN112924694A CN 112924694 A CN112924694 A CN 112924694A CN 201911240786 A CN201911240786 A CN 201911240786A CN 112924694 A CN112924694 A CN 112924694A
- Authority
- CN
- China
- Prior art keywords
- protein
- ligand
- group
- proteins
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 148
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 146
- 238000004458 analytical method Methods 0.000 title claims abstract description 14
- 239000003446 ligand Substances 0.000 claims abstract description 62
- 238000000034 method Methods 0.000 claims abstract description 48
- 238000010438 heat treatment Methods 0.000 claims abstract description 35
- 239000006228 supernatant Substances 0.000 claims abstract description 15
- 238000002844 melting Methods 0.000 claims abstract description 10
- 230000008018 melting Effects 0.000 claims abstract description 10
- 238000012216 screening Methods 0.000 claims abstract description 5
- 229940079593 drug Drugs 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 239000012460 protein solution Substances 0.000 claims description 8
- 238000011002 quantification Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 238000004949 mass spectrometry Methods 0.000 claims description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 239000002953 phosphate buffered saline Substances 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000002207 metabolite Substances 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 238000004445 quantitative analysis Methods 0.000 claims description 3
- 238000010257 thawing Methods 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 230000009089 cytolysis Effects 0.000 claims description 2
- 238000004925 denaturation Methods 0.000 claims description 2
- 230000036425 denaturation Effects 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 238000000265 homogenisation Methods 0.000 claims description 2
- 238000011534 incubation Methods 0.000 claims description 2
- 238000003368 label free method Methods 0.000 claims description 2
- 229910021645 metal ion Inorganic materials 0.000 claims description 2
- 238000003672 processing method Methods 0.000 claims description 2
- 238000000751 protein extraction Methods 0.000 claims description 2
- 238000000575 proteomic method Methods 0.000 claims 3
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 238000007405 data analysis Methods 0.000 claims 1
- 230000007071 enzymatic hydrolysis Effects 0.000 claims 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000017854 proteolysis Effects 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 238000002474 experimental method Methods 0.000 abstract description 5
- 230000003993 interaction Effects 0.000 abstract description 5
- 230000001788 irregular Effects 0.000 abstract 1
- 230000031070 response to heat Effects 0.000 abstract 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 12
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 12
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 239000000523 sample Substances 0.000 description 9
- 108010033276 Peptide Fragments Proteins 0.000 description 8
- 102000007079 Peptide Fragments Human genes 0.000 description 8
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 238000003556 assay Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- HWCKGOZZJDHMNC-UHFFFAOYSA-M tetraethylammonium bromide Chemical compound [Br-].CC[N+](CC)(CC)CC HWCKGOZZJDHMNC-UHFFFAOYSA-M 0.000 description 4
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 239000013595 supernatant sample Substances 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000021527 ATP binding proteins Human genes 0.000 description 1
- 108091011108 ATP binding proteins Proteins 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- VGGGPCQERPFHOB-UHFFFAOYSA-N Bestatin Natural products CC(C)CC(C(O)=O)NC(=O)C(O)C(N)CC1=CC=CC=C1 VGGGPCQERPFHOB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- LTLYEAJONXGNFG-DCAQKATOSA-N E64 Chemical compound NC(=N)NCCCCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O LTLYEAJONXGNFG-DCAQKATOSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- MGSKVZWGBWPBTF-UHFFFAOYSA-N aebsf Chemical compound NCCC1=CC=C(S(F)(=O)=O)C=C1 MGSKVZWGBWPBTF-UHFFFAOYSA-N 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- AFQIYTIJXGTIEY-UHFFFAOYSA-N hydrogen carbonate;triethylazanium Chemical compound OC(O)=O.CCN(CC)CC AFQIYTIJXGTIEY-UHFFFAOYSA-N 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012509 protein identification method Methods 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000006318 protein oxidation Effects 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The present invention relates to a discrimination-free method for analyzing thermal stability of a protein, which is used for screening a target protein having an interaction with a ligand molecule. Taking a protein sample, adding and adding ligand molecules respectively, incubating, heating, separating supernatant, performing enzymolysis and quantitative proteomics analysis, and calculating the difference of protein quantitative results of a ligand group and a blank group to screen out the ligand target protein. The invention only carries out experiments at the temperature points with great changes of the thermal stability of most proteins, omits the temperature points which have no significance for the identification of ligand molecule target proteins, directly calculates the difference of the proteins of a ligand group and a blank group without fitting a curve to calculate the delta Tm, more intuitively reflects the difference of the thermal stability of the proteins of the target proteins added into the ligand group and the blank group, also can avoid that a plurality of target proteins with irregular melting curves are omitted due to the incapability of calculating the delta Tm, is suitable for all proteins with response to heat, and improves the coverage of the identification of the target proteins.
Description
Technical Field
The invention belongs to the technical field of interaction of protein and ligand molecules in the proteomic research direction, and particularly relates to a high-sensitivity high-coverage ligand target protein identification method and application thereof.
Background
The comprehensive and accurate identification of target and off-target proteins of drug molecules has always been a major challenge in the field of drug research. In recent years, with the rapid development of mass spectrometry technology, several mass spectrometry-based proteomics technologies are beginning to be applied to the identification of drug molecule target proteins. In addition to having a higher throughput, these techniques allow better identification of direct and indirect target proteins of drug molecules without requiring any modification of the drug molecule. Which comprises the following steps: drug affinity response Target stability method (DARTS) (Target identification using drug affinity reactivity stability (DARTS), Proc. Natl Acad. Sci. USA 106, 21984-21989 (2009)), restriction enzyme cleavage method (LIP) (A Map of Protein-metabolism Interactions derivatives of Chemical Communication, Cell,172,358-372.e23(2018)), Protein oxidation rate stability method (SPROX) (Thermokinetic analysis of Protein-ligand binding Interactions in complex biological chemistry using the stability of Protein from oxidation rate stability (SPROX 346, 148-161. 2013) and Protein thermal stability analysis method (TPR 5784) (Target identification using drug affinity reactivity stability of Protein stability of Protein 12542, 20147. Nat. Proc. 8, 148-161. and 2013) (TPR 5784). The main drawback of the first three methods is the need to identify and quantify specific peptide stretches, which is rather difficult due to the influence of the dynamic range of the protein and the mass spectrometric identification.
The protein thermal stability analysis method utilizes the difference of thermal stability of target protein of drug molecules before and after combining with the drug molecules, so that the amount of protein precipitated after heating at the same temperature is different, and then combines with a mass spectrometry quantitative technology to search for differential protein, namely potential target protein. Protein thermostability assays are widely used in the study of interactions between proteins and drug molecules, proteins and metabolites, proteins and nucleic acids, proteins and proteins, and the like. However, the conventional thermal protein analysis method has obvious defects in both experimental process and data processing. The experimental group and the control group are divided into different samples, and the subsequent treatment and mass spectrum quantification process are easy to bring about larger influence and the like. Several redundant temperature points were used with no significant change in protein thermostability, and Δ T was calculated only to fit an "S" -shaped melting curve when processing the datamHowever, for many proteins without regular melting curves, it is not possible to fit an "S" shaped curve at all to calculate Δ TmThus missing, is a method of discrimination.
In fact, when the target protein is screened, what really makes sense is the temperature range which can cause the difference between the thermal stability of the proteins of the drug adding group and the control group, and the difference can really reflect the change degree of the thermal stability of the target protein before and after the drug molecules are combined, rather than the calculated delta Tm after the curve is fitted by the traditional method.
In view of the above problems, we propose to invent a method for ligand target protein identification which is simpler and has higher identification sensitivity and coverage.
The above documents do not describe any method for analyzing the thermal stability of proteins based on non-discrimination, nor do they suggest any method.
Disclosure of Invention
The invention aims to provide a method for identifying ligand molecule target protein with high sensitivity and high coverage.
1. The method screens the ligand target protein by utilizing the direct difference of the ligand target protein in a ligand group and a blank group after heating precipitation instead of the protein melting point difference calculated by fitting a melting curve. The high sensitivity and high coverage identification of the ligand molecule interacting protein is realized by performing mass spectrum quantification on the protein in the supernatant sample after heating and centrifugation and directly analyzing the difference.
2. The invention adopts the following technical scheme:
(a) determining an optimal temperature interval for the protein mixture to precipitate;
(b) incubating the protein mixture with the ligand molecules respectively;
(c) heating in the optimum temperature interval to cause protein denaturation and precipitation;
(d) separating the heated supernatant for enzymolysis and quantitative proteomics analysis;
(e) and directly analyzing the difference of the protein quantitative results of the ligand group and the blank group, and screening the ligand molecule target protein.
3. The protein sample in the steps (a) and (b) may be a cell extract, a tissue extract, a protein mixture such as blood, or a purified protein.
4. The protein sample must retain the intact native structure of the protein and must not be denatured. Some gentle methods of protein extraction should be taken, including: a liquid nitrogen repeated freeze thawing method, a liquid nitrogen grinding method, a homogenization method and the like; the lysis solution used should also be able to maintain the structure of the protein, including Phosphate Buffered Saline (PBS) and the like.
5. The specific steps for determining the optimum temperature interval in the step (a) are as follows: the method comprises the steps of measuring protein solution in an equal amount in a plurality of new EP tubes, heating at different temperatures within the temperature range of 37-75 ℃, separating the heated supernatant, performing enzymolysis and quantitative proteomics analysis, and calculating the amount of residual protein in the supernatant at different temperatures. The temperature point at which most of the protein precipitates significantly is selected as the optimum temperature range.
6. The optimum temperature range selected by the invention is 47-59 ℃, but the temperature range is not limited to, and the temperature range can be adjusted according to specific conditions.
7. The ligand molecule of step (a) may be an active drug, a metabolite, a nucleic acid molecule, a metal ion, a peptide fragment, a protein, or any other molecule that may interact with a protein.
8. The protein solution of step (a) is divided equally into two groups, one group is added with ligand molecules with certain final concentration as ligand group, and the other group is added with blank solvent with equal volume as blank group for incubation. But not limited to two groups, the ligand group can also be added with a series of ligands with different final concentrations, and the blank group can also be molecules or blanks with similar structures.
9. The heating temperature in the step (c) comprises any two or more temperature points in the optimal temperature interval.
10. The heating induced protein precipitation method in the step (c) comprises the following specific steps: based on the number of the set heating temperature points, the protein solutions of the base group and the blank group were weighed in equal amounts in a new EP tube and heated at a set temperature.
11. The quantitative proteomics analysis method of step (d) includes label-free quantification and label quantification, and a suitable quantification method can be selected according to the number of actual samples.
12. The data processing method in the step (e) is specifically as follows: and (4) carrying out library searching on raw files obtained by mass spectrometry by using conventional proteomics analysis software, and setting a corresponding quantitative method. And (3) selecting the protein with higher quantitative result reliability from the obtained quantitative results, and carrying out normalization treatment. And (3) directly calculating the difference of the quantitative values of the proteins in the ligand group and the blank group, setting a proper threshold value, and obtaining the protein which meets the set threshold value as the potential target protein of the ligand molecules.
13. The protein with high reliability of the quantitative result comprises at least two or more than two peptide fragments and has quantitative result.
14. The difference between the protein added to the ligand group and the blank group comprises the distance or Euclidean distance between two protein melting curves, the area between the two curves and the like.
15. The threshold value can be adjusted according to different ligand molecules.
The invention has the following advantages:
1. the flux is high. Under the condition of not needing any modification to the ligand molecules, the target protein of the ligand molecules can be screened out at high flux by using a mass spectrometry quantitative method
2. The operation is simple, and the cost is saved. Compared with the traditional protein thermal stability analysis method, the method only selects the temperature points with great changes in the thermal stability of most proteins for experiment, saves redundant temperature points, simplifies experiment operation and saves reagent cost and mass spectrum time.
3. The quantitative accuracy is high. Because the ligand group and the blank group are mixed in the same sample, the experimental error caused by subsequent experimental operation and mass spectrum identification is avoided, and the reliability of the experimental result is greatly improved.
4, strong universality, wide coverage and no discrimination. The difference of the proteins of the ligand group and the control group at five temperature points is directly calculated without fitting a curve to calculate the delta Tm, so that the omission of a part of proteins due to the fact that the delta Tm cannot be calculated due to the absence of a regular melting curve is avoided, the change of the thermal stability of the ligand target protein before and after the ligand target protein is combined with ligand molecules is more intuitively reflected, and the coverage of ligand target protein identification is improved
Drawings
FIG. 1 is a graph showing the ratio distribution of the proteins remaining in the supernatant after heating at the different temperatures. The abscissa is the different heating temperatures and the ordinate is the ratio of the amount of protein remaining in the supernatant to the amount of protein at 37 ℃.
FIG. 2 is a flow chart of a novel method for non-discriminatory protein thermostability analysis.
FIG. 3 is the experimental results of the novel discrimination-free protein thermostability assay for identifying a staurosporine target protein. (a) Classification of all target proteins by threshold screening (abscissa represents classification of target protein, ordinate represents sum of distance of protein in supernatant sample and sediment sample, number represents number of such protein). (b) The Staurosporine target protein identified by the method is compared with the Overlap of the Staurosporine target protein identified by the traditional method. (c) Distance density comparison graph of staurosporine target protein identified by the method of the invention and staurosporine target protein identified by the traditional method (the abscissa is the distance between the ligand group and blank group melting curves of the protein, and the ordinate is the density size).
From the distribution in FIG. 1, it can be seen that at lower heating temperatures (<47 ℃) most of the proteins have not precipitated or have just begun to precipitate, and at higher heating temperatures (>59 ℃) most of the proteins have precipitated substantially completely, which are not sufficient to cause a significant difference in the thermostability of the ligand target proteins in the ligand and blank groups, and do not contribute to the identification of the ligand target proteins. In contrast, the vast majority of proteins only partially precipitate when heated in the intermediate temperature range (47-59 ℃), and this can vary significantly whether ligand addition causes stabilization or destabilization of the target protein. Therefore, the temperature range of 47-59 ℃ is selected as the optimum temperature range. The selection of the optimum temperature range can also be changed according to specific requirements.
Detailed Description
The invention is further illustrated by the following examples, which are not intended to limit the scope of the invention.
Example 1
Novel methods for the non-discriminatory protein thermostability assay were used for the target protein study of staurosporine (star cyclosporine):
(1) taking 1 dish of K562 cell sample, suspending in 600 μ L PBS buffer solution, adding 1% protease inhibitor (dimethyl sulfoxide (DMSO) solution of mixture composed of AEBSF, aprotinin, bestatin, E-64, leupeptin and pepstatin A) with final volume concentration, repeatedly freezing and thawing for three times by liquid nitrogen, centrifuging at 20000g for 10min at 4 deg.C, and collecting supernatant sample;
(2) 50 μ L of each of the above protein samples were heated in eleven new EP tubes at 37 deg.C, 41 deg.C, 44 deg.C, 47 deg.C, 50 deg.C, 53 deg.C, 56 deg.C, 59 deg.C, 62 deg.C, 65 deg.C, 68 deg.C for 3min, then cooled at room temperature for 2min, and then centrifuged at 4 deg.C, 20000g for 10 min. 30. mu.L of the supernatant from each EP tube was placed in eleven new EP tubes and Trypsin (Trypsin) was performed separately. Finally, the obtained peptide fragment solutions are respectively redissolved in 0.1% (v/v) formic acid solution for LC-MS/MS analysis. And (3) removing the residual protein amount of the supernatant corresponding to other heating temperatures by using the residual protein amount of the supernatant corresponding to 37 ℃, calculating the relative amount of the residual protein of the supernatant at different temperatures, and finally selecting 47-59 ℃ as an optimal heating temperature interval for subsequent experiments.
(3) The protein solution obtained in the step (1) is divided into two parts on average, wherein one part is added with staurosporine (the staurosporine is dissolved in DMSO) with the final concentration of 25 mu M, the other part is added with DMSO with the same volume, and the two samples are incubated for 30min at room temperature at the same time;
(4) two samples of 50. mu.L each were placed in five new 200. mu.L PCR tubes, heated at 47 ℃,50 ℃,53 ℃,56 ℃,59 ℃ for 3min, cooled at room temperature for 2min, and centrifuged at 4 ℃ and 20000g for 10min to collect the supernatant;
(5) mu.L of the supernatant from each PCR tube was placed in a new 600. mu.L EP tube, and 90. mu.L of a buffer containing 66mM TEAB (triethylamine-carbonate buffer) and 8M Gua-HCl (guanidine hydrochloride) was added;
(6) adding TCEP (tris (2-carboxyethyl) phosphine) with a final concentration of 10mM and CAA (chloroacetamide) with a final concentration of 40mM to the protein solution, and heating in a water bath at 95 ℃ for 5min to perform denaturing reductive alkylation;
(7) transferring the protein solution to an ultrafiltration tube membrane with the molecular weight cutoff of 10K, performing ultrafiltration centrifugation under 14000g of centrifugal force, washing twice with 50mM TEAB, adding 150 mu L of 50mM TEAB and 6 mu g of trypsin, and performing enzymolysis for 16h in water bath at 37 ℃;
(8) centrifuging the enzyme-hydrolyzed sample under 14000g to obtain a peptide fragment solution, washing the ultrafiltration membrane once by using 100 mu L of 50mM TEAB, and combining corresponding washing liquid and the peptide fragment solution;
(9) the concentration of the obtained peptide fragment solution was measured by Nanodrop.
(10) Adding corresponding TMT labeling reagent (TMT) into the peptide fragment sample of the step (8) according to the mass ratio of the maximum labeling reagent amount to the protein amount of 4/110-126,TMT10-127N,TMT10-127C,TMT10-128N,TMT10-128C,TMT10-129N,TMT10-129C,TMT10-130N,TMT10-130C,TMT10The-131 samples respectively correspond to the labeling blank group at 47 ℃,50 ℃,53 ℃,56 ℃,59 ℃ and the ligand group at 47 ℃,50 ℃,53 ℃,56 ℃ and 59 ℃, and after shaking for 60min at room temperature, 1 mu L of hydroxylamine solution with the volume concentration of 5 percent is added, and the shaking is carried out for 20min at room temperature.
(11) Mixing all the ten ligand group samples and the blank group samples in the step (10) into one sample, and performing freeze-drying preservation;
(12) re-dissolving the sample of step (11) in 5mM NH4HCO3Respectively carrying out high-pH reverse grading in an ammonium bicarbonate solution, collecting fractions, and freeze-drying and storing;
(13) the peptide fragment mixture obtained above was reconstituted with 0.1% (v/v) formic acid and analyzed by RP LC-MS/MS.
FIG. 3 is a graph showing the results of the experiments conducted on Staurosporine target protein in the novel non-discriminatory protein thermostability assay. Staurosporine is a broad spectrum ATP competitive kinase inhibitor, binds mainly in the ATP binding pocket region of kinases, so its theoretical target protein should be some protein kinases or proteins with ATP binding pockets. As shown in fig. (a), 117 proteins having a distance D between the melting curves of the blank and the control greater than 0.17 or less than-0.4, among which 106 proteins became more stable (D >0.17), in which the number of kinases was 78, were considered as target proteins of staurosporine; 11 proteins became more unstable (D < -0.4) with a number of kinases of 3. And most of the proteins that are not kinase targets are ATP-binding proteins or regulatory subunits of kinases (fig. 3(b)), suggesting that these proteins, although not kinases, are still likely to be direct or indirect targets of staurosporine. Therefore, the method has higher reliability and accuracy.
Compared to the work published by Mikhail's in Science (FIG. 3(c)), the number of kinases identified in this example was 1.6 times greater, 60% greater, and could cover more than 70%. As can be seen from FIG. 3(b), the present invention has a better recognition effect for proteins with less change in protein thermal stability after ligand addition. In conclusion, the method has higher identification sensitivity and deeper coverage.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911240786.3A CN112924694A (en) | 2019-12-06 | 2019-12-06 | Discrimination-free protein thermal stability analysis method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911240786.3A CN112924694A (en) | 2019-12-06 | 2019-12-06 | Discrimination-free protein thermal stability analysis method |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112924694A true CN112924694A (en) | 2021-06-08 |
Family
ID=76161494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911240786.3A Pending CN112924694A (en) | 2019-12-06 | 2019-12-06 | Discrimination-free protein thermal stability analysis method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112924694A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117451580A (en) * | 2023-12-26 | 2024-01-26 | 中国农业科学院农产品加工研究所 | Method for analyzing extrusion stability of wiredrawing protein |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103733067A (en) * | 2011-04-18 | 2014-04-16 | 艾维特拉普罗特玛公司 | Methods for determining ligand binding to a target protein using a thermal shift assay |
CN107884370A (en) * | 2016-09-30 | 2018-04-06 | 斯帕克生物制药有限公司 | The method for identifying the target proteins matter of drug molecule |
CN109799350A (en) * | 2019-01-17 | 2019-05-24 | 暨南大学 | Albumen thermostabilization measurement combines two-way stable isotope labelling protein science screening medicine target calibration method and application |
US20190227062A1 (en) * | 2016-09-26 | 2019-07-25 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods for identifying proteins that bind ligands |
-
2019
- 2019-12-06 CN CN201911240786.3A patent/CN112924694A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103733067A (en) * | 2011-04-18 | 2014-04-16 | 艾维特拉普罗特玛公司 | Methods for determining ligand binding to a target protein using a thermal shift assay |
US20190227062A1 (en) * | 2016-09-26 | 2019-07-25 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods for identifying proteins that bind ligands |
CN107884370A (en) * | 2016-09-30 | 2018-04-06 | 斯帕克生物制药有限公司 | The method for identifying the target proteins matter of drug molecule |
CN109799350A (en) * | 2019-01-17 | 2019-05-24 | 暨南大学 | Albumen thermostabilization measurement combines two-way stable isotope labelling protein science screening medicine target calibration method and application |
Non-Patent Citations (2)
Title |
---|
HOLGER FRANKEN等: "Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry", 《NATURE PROTOCOLS》 * |
吴晓林: "基于生物信息学分析的玉米EMB564蛋白的理化性质研究", 《中国优秀硕士学位论文全文数据库 农业科技辑》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117451580A (en) * | 2023-12-26 | 2024-01-26 | 中国农业科学院农产品加工研究所 | Method for analyzing extrusion stability of wiredrawing protein |
CN117451580B (en) * | 2023-12-26 | 2024-04-16 | 中国农业科学院农产品加工研究所 | Analysis method of extrusion stability of drawn protein |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tammen et al. | Peptidomic analysis of human blood specimens: comparison between plasma specimens and serum by differential peptide display | |
CN107110867A (en) | Biomarker for diagnosing cancer of liver and application thereof | |
CN115678994B (en) | A biomarker combination, a reagent containing the same and its application | |
JP2010048825A (en) | Rapid and quantitative proteome analysis and related methods | |
WO2018133778A1 (en) | Preparation method for urine protein and detection method for urine proteome | |
CN110133136A (en) | A method for identification of BPDE adducted target protein | |
WO2023134169A1 (en) | Pretreatment method, storage method, automatic treatment system, and detection method for urine sample | |
Patterson | How much of the proteome do we see with discovery-based proteomics methods and how much do we need to see? | |
Moshkovskii et al. | Acute phase serum amyloid A in ovarian cancer as an important component of proteome diagnostic profiling | |
Magni et al. | Biomarkers discovery by peptide and protein profiling in biological fluids based on functionalized magnetic beads purification and mass spectrometry | |
CN112485442A (en) | Small molecule target screening method based on chemical proteomics and application thereof | |
CN112924694A (en) | Discrimination-free protein thermal stability analysis method | |
CN109342743B (en) | Preparation method of denatured IgG capable of being efficiently combined with rheumatoid factor | |
Oehr | New Biomarkers for Screening of Early Tumors Stage | |
CN119044386A (en) | Nanomaterial enrichment assisted boost strategy for deep quantification of non-enriched plasma and serum proteomes | |
High et al. | Deep proteome profiling by isobaric labeling, extensive liquid chromatography, mass spectrometry, and software-assisted quantification | |
CN103698418B (en) | Quantitative detection method of transgenic protein CP4-EPSPS in plants | |
CN113687002A (en) | Quality control method for eliminating sample heterogeneity and high abundance interference capability | |
O’Brien et al. | Employing TMT quantification in a shotgun-MS platform | |
CN102401813B (en) | A Rapid Analytical Method for Variant Hemoglobin | |
CN109100461B (en) | Method for distinguishing organic rice from non-organic rice by utilizing proteomics technology | |
Cho et al. | Statistical identification of differentially labeled peptides from liquid chromatography tandem mass spectrometry | |
CN111551749A (en) | A method for identifying drug target proteins | |
Heegaard et al. | Important options available—from start to finish—for translating proteomics results to clinical chemistry | |
CN110873766A (en) | Mass spectrometry method for screening protein with structure and interaction change caused by drug |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210608 |
|
WD01 | Invention patent application deemed withdrawn after publication |